[go: up one dir, main page]

Guzelj et al., 2021 - Google Patents

Structural fine-tuning of desmuramylpeptide NOD2 agonists defines their in vivo adjuvant activity

Guzelj et al., 2021

View PDF
Document ID
17196921157249001745
Author
Guzelj S
Nabergoj S
Gobec M
Pajk S
Klančič V
Slütter B
Frkanec R
Štimac A
Šket P
Plavec J
Mlinarič-Raščan I
Jakopin Z
Publication year
Publication venue
Journal of medicinal chemistry

External Links

Snippet

We report on the design, synthesis, and biological evaluation of a series of nucleotide- binding oligomerization-domain-containing protein 2 (NOD2) desmuramylpeptide agonists with improved in vitro and in vivo adjuvant properties. We identified two promising …
Continue reading at pubs.acs.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Similar Documents

Publication Publication Date Title
Guzelj et al. Structural fine-tuning of desmuramylpeptide NOD2 agonists defines their in vivo adjuvant activity
Bhandari et al. The role of ClpP protease in bacterial pathogenesis and human diseases
Bersch et al. Bacterial peptidoglycan fragments differentially regulate innate immune signaling
Gobec et al. Discovery of nanomolar desmuramylpeptide agonists of the innate immune receptor nucleotide-binding oligomerization domain-containing protein 2 (NOD2) possessing immunostimulatory properties
Bergan et al. Shiga toxins
Geddes et al. Unleashing the therapeutic potential of NOD-like receptors
RU2668560C2 (en) Conjugate vaccine on basis of antigen wt1 peptide
Alpdundar Bulut et al. Human gut commensal membrane vesicles modulate inflammation by generating M2-like macrophages and myeloid-derived suppressor cells
Kaur et al. TLR2 agonistic small molecules: detailed structure–activity relationship, applications, and future prospects
Zom et al. Dual synthetic peptide conjugate vaccine simultaneously triggers TLR2 and NOD2 and activates human dendritic cells
Agnihotri et al. Structure− activity relationships in nucleotide oligomerization domain 1 (Nod1) agonistic γ-glutamyldiaminopimelic acid derivatives
Morin et al. Diprovocims: a new and exceptionally potent class of toll-like receptor agonists
Jakopin et al. Immunomodulatory properties of novel nucleotide oligomerization domain 2 (Nod2) agonistic desmuramyldipeptides
BR112013018046B1 (en) PEPTIDE CONJUGATE, PHARMACEUTICAL COMPOSITION, IN VITRO METHODS TO BLOCK SIGNALING BY ONE OR MORE CYTOKINE-YC FAMILY MEMBERS AND TO INHIBIT BINDING OF CYTOKINE-YC TO THE YC-SUBSUIT AND USE OF PEPTIDE CONJUGATE OR PHARMACEUTICAL COMPOSITION
Morin et al. Discovery and structure–activity relationships of the neoseptins: a new class of Toll-like receptor-4 (TLR4) agonists
Fujimoto et al. Structures, synthesis, and human Nod1 stimulation of immunostimulatory bacterial peptidoglycan fragments in the environment
AU2008302356A1 (en) Compositions and methods for treating inflammation and inflammation-related disorders by Plectranthus Amboinicus extracts
Effenberg et al. Nonpyrogenic molecular adjuvants based on norAbu-muramyldipeptide and norAbu-glucosaminyl muramyldipeptide: Synthesis, molecular mechanisms of action, and biological activities in vitro and in vivo
van de Graaff et al. Conditionally controlling human TLR2 activity via trans-cyclooctene caged ligands
Cai et al. Convergent synthesis of novel muramyl dipeptide analogues: inhibition of porphyromonas gingivalis-induced pro-inflammatory effects by high doses of muramyl dipeptide
Madge et al. Structure–activity analysis of cyclic multicomponent lipopeptide self-adjuvanting vaccine candidates presenting group A streptococcus antigens
CN114956977B (en) A biphenyl compound, pharmaceutical composition and preparation method and application thereof
Szekely et al. Design, synthesis, and immunological evaluation of a multicomponent construct based on a glycotripeptoid core comprising B and T cell epitopes and a toll-like receptor 7 agonist that elicits potent immune responses
US8569245B2 (en) Protease inhibitors, compositions and methods of use
Yang et al. Next-generation diprovocims with potent human and murine TLR1/TLR2 agonist activity that activate the innate and adaptive immune response